Replacement of E-cadherin by N-cadherin in the mammary gland leads to fibrocystic changes and tumor formation

Breast Cancer Research

Volumn 13, Issue 5, 2011, Pages

  Kotb, Ahmed M ^a   Hierholzer, Andreas ^a   Kemler, Rolf ^a  

^a MAX PLANCK INSTITUTE OF IMMUNOBIOLOGY AND EPIGENETICS   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

FIBROBLAST GROWTH FACTOR; NERVE CELL ADHESION MOLECULE; PROTEIN P53; UVOMORULIN; CADHERIN; CDH2 PROTEIN, MOUSE;

ALLELE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CARCINOGENESIS; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; FIBROCYSTIC BREAST DISEASE; GENE INACTIVATION; HETEROZYGOSITY; LACTATION; MAMMARY GLAND; MOUSE; NONHUMAN; PHENOTYPE; PROTEIN EXPRESSION; THIRD TRIMESTER PREGNANCY; AGE; ANIMAL; BREAST CYST; CELL MOTION; CYTOLOGY; EPITHELIUM CELL; EXPERIMENTAL NEOPLASM; FIBROSIS; GENE SILENCING; GENETICS; METABOLISM; PATHOLOGY; PREGNANCY; TRANSGENIC MOUSE; TUMOR SUPPRESSOR GENE; UDDER;

AGE FACTORS; ANIMALS; APOPTOSIS; BREAST CYST; CADHERINS; CELL MOVEMENT; EPITHELIAL CELLS; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; FIBROBLAST GROWTH FACTORS; FIBROCYSTIC BREAST DISEASE; FIBROSIS; GENE SILENCING; GENES, P53; LACTATION; MAMMARY GLANDS, ANIMAL; MAMMARY NEOPLASMS, ANIMAL; MICE; MICE, TRANSGENIC; PREGNANCY;

EID: 83155172643     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr3046     Document Type: Article

References (57)

1. Takeichi M. Morphogenetic roles of classic cadherins. Curr Opin Cell Biol 1995, 7:619-627. 10.1016/0955-0674(95)80102-2, 8573335.
2. Stemmler MP. Cadherins in development and cancer. Mol Biosyst 2008, 4:835-850. 10.1039/b719215k, 18633485.
3. Radice GL, Rayburn H, Matsunami H, Knudsen KA, Takeichi M, Hynes RO. Developmental defects in mouse embryos lacking N-cadherin. Dev Biol 1997, 181:64-78. 10.1006/dbio.1996.8443, 9015265.
4. Ozawa M, Baribault H, Kemler R. The cytoplasmic domain of the cell adhesion molecule uvomorulin associates with three independent proteins structurally related in different species. EMBO J 1989, 8:1711-1717. 401013, 2788574.
5. Hoschuetzky H, Aberle H, Kemler R. Beta-catenin mediates the interaction of the cadherin-catenin complex with epidermal growth factor receptor. J Cell Biol 1994, 127:1375-1380. 10.1083/jcb.127.5.1375, 2120252, 7962096.
6. Williams EJ, Furness J, Walsh FS, Doherty P. Activation of the FGF receptor underlies neurite outgrowth stimulated by L1, N-CAM, and N-cadherin. Neuron 1994, 13:583-594. 10.1016/0896-6273(94)90027-2, 7917292.
7. Kan NG, Stemmler MP, Junghans D, Kanzler B, de Vries WN, Dominis M, Kemler R. Gene replacement reveals a specific role for E-cadherin in the formation of a functional trophectoderm. Development 2007, 134:31-41. 10.1242/dev.02722, 17138661.
8. Libusova L, Stemmler MP, Hierholzer A, Schwarz H, Kemler R. N-cadherin can structurally substitute for E-cadherin during intestinal development but leads to polyp formation. Development 2010, 137:2297-2305. 10.1242/dev.048488, 20534673.
9. Brisken C, Rajaram RD. Alveolar and lactogenic differentiation. J Mammary Gland Biol Neoplasia 2006, 11:239-248. 10.1007/s10911-006-9026-0, 17111223.
10. Faraldo MM, Teuliere J, Deugnier MA, Taddei-De La Hosseraye I, Thiery JP, Glukhova MA. Myoepithelial cells in the control of mammary development and tumorigenesis: data from genetically modified mice. J Mammary Gland Biol Neoplasia 2005, 10:211-219. 10.1007/s10911-005-9582-8, 16807801.
11. Boussadia O, Kutsch S, Hierholzer A, Delmas V, Kemler R. E-cadherin is a survival factor for the lactating mouse mammary gland. Mech Dev 2002, 115:53-62. 10.1016/S0925-4773(02)00090-4, 12049767.
12. Wagner KU, Wall RJ, St-Onge L, Gruss P, Wynshaw-Boris A, Garrett L, Li M, Furth PA, Hennighausen L. Cre-mediated gene deletion in the mammary gland. Nucleic Acids Res 1997, 25:4323-4330. 10.1093/nar/25.21.4323, 147032, 9336464.
13. Derksen PWB, Liu X, Saridin F, van der Gulden H, Zevenhoven J, Evers B, van Beijnum JR, Griffioen AW, Vink J, Krimpenfort P. Somatic inactivation of E-cadherin and p53 in mice leads to metastatic lobular mammary carcinoma through induction of anoikis resistance and angiogenesis. Cancer Cell 2006, 10:437-449. 10.1016/j.ccr.2006.09.013, 17097565.
14. Jonkers J, Meuwissen R, van der Gulden H, Peterse H, van der Valk M, Berns A. Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer. Nat Genet 2001, 29:418-425. 10.1038/ng747, 11694875.
15. Miyoshi K. Mammary Epithelial Cells Are Not Able to Undergo Pregnancy-Dependent Differentiation in the Absence of the Helix-Loop-Helix Inhibitor Id2. Molecular Endocrinology 2002, 16:2892-2901. 10.1210/me.2002-0128, 12456807.
16. Bancroft JD, Stevens A. Theory and practice of histological techniques. 1990, Edinburgh; New York: Churchill Livingstone, 3.
17. Batlle E, Henderson JT, Beghtel H, van den Born MM, Sancho E, Huls G, Meeldijk J, Robertson J, van de Wetering M, Pawson T, Clevers H. Beta-catenin and TCF mediate cell positioning in the intestinal epithelium by controlling the expression of EphB/ephrinB. Cell 2002, 111:251-263. 10.1016/S0092-8674(02)01015-2, 12408869.
18. Vestweber D, Kemler R. Rabbit antiserum against a purified surface glycoprotein decompacts mouse preimplantation embryos and reacts with specific adult tissues. Exp Cell Res 1984, 152:169-178. 10.1016/0014-4827(84)90241-6, 6370707.
19. Humphreys RC, Hennighausen L. Signal transducer and activator of transcription 5a influences mammary epithelial cell survival and tumorigenesis. Cell Growth Differ 1999, 10:685-694.
20. Soriano P. Generalized lacZ expression with the ROSA26 Cre reporter strain. Nat Genet 1999, 21:70-71. 10.1038/5007, 9916792.
21. Clarkson RW, Boland MP, Kritikou EA, Lee JM, Freeman TC, Tiffen PG, Watson CJ. The genes induced by signal transducer and activators of transcription (STAT)3 and STAT5 in mammary epithelial cells define the roles of these STATs in mammary development. Mol Endocrinol 2006, 20:675-685.
22. Sheppard MN. The pathology of cystic fibrosis. Curr Diagnc Pathol 2002, 8:50-59.
23. Garcia FU, Galindo LM, Holsclaw DS. Breast abnormalities in patients with cystic fibrosis: previously unrecognized changes. Ann Diagn Pathol 1998, 2:281-285. 10.1016/S1092-9134(98)80019-1, 9845750.
24. Mailhot G, Rabasa-Lhoret R, Moreau A, Berthiaume Y, Levy E. CFTR depletion results in changes in fatty acid composition and promotes lipogenesis in intestinal Caco 2/15 cells. PLoS One 2010, 5:e10446. 10.1371/journal.pone.0010446, 2864762, 20463919.
25. Mailhot G, Ravid Z, Barchi S, Moreau A, Rabasa-Lhoret R, Levy E. CFTR knockdown stimulates lipid synthesis and transport in intestinal Caco-2/15 cells. Am J Physiol Gastrointest Liver Physiol 2009, 297:G1239-1249. 10.1152/ajpgi.00206.2009, 19808659.
26. Dailey L, Ambrosetti D, Mansukhani A, Basilico C. Mechanisms underlying differential responses to FGF signaling. Cytokine Growth Factor Rev 2005, 16:233-247. 10.1016/j.cytogfr.2005.01.007, 15863038.
27. Lovicu FJ, McAvoy JW. FGF-induced lens cell proliferation and differentiation is dependent on MAPK (ERK1/2) signalling. Development 2001, 128:5075-5084.
28. Mohammadi M, McMahon G, Sun L, Tang C, Hirth P, Yeh BK, Hubbard SR, Schlessinger J. Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors. Science 1997, 276:955-960. 10.1126/science.276.5314.955, 9139660.
29. Chen Y, Shi L, Zhang L, Li R, Liang J, Yu W, Sun L, Yang X, Wang Y, Zhang Y, Shang Y. The molecular mechanism governing the oncogenic potential of SOX2 in breast cancer. J Biol Chem 2008, 283:17969-17978. 10.1074/jbc.M802917200, 18456656.
30. Zhang H, Stephens LC, Kumar R. Metastasis tumor antigen family proteins during breast cancer progression and metastasis in a reliable mouse model for human breast cancer. Clin Cancer Res 2006, 12:1479-1486. 10.1158/1078-0432.CCR-05-1519, 16533771.
31. Singh RR, Kumar R. MTA family of transcriptional metaregulators in mammary gland morphogenesis and breast cancer. J Mammary Gland Biol Neoplasia 2007, 12:115-125. 10.1007/s10911-007-9043-7, 17549610.
32. Jerry DJ, Pinkas J, Kuperwasser C, Dickinson ES, Naber SP. Regulation of p53 and its targets during involution of the mammary gland. J Mammary Gland Biol Neoplasia 1999, 4:177-181. 10.1023/A:1018777224808, 10426396.
33. Derksen PW, Liu X, Saridin F, van der Gulden H, Zevenhoven J, Evers B, van Beijnum JR, Griffioen AW, Vink J, Krimpenfort P, Peterse JL, Cardiff RD, Berns A, Jonkers J. Somatic inactivation of E-cadherin and p53 in mice leads to metastatic lobular mammary carcinoma through induction of anoikis resistance and angiogenesis. Cancer Cell 2006, 10:437-449. 10.1016/j.ccr.2006.09.013, 17097565.
34. Daniel CW, Strickland P, Friedmann Y. Expression and functional role of E- and P-cadherins in mouse mammary ductal morphogenesis and growth. Dev Biol 1995, 169:511-519. 10.1006/dbio.1995.1165, 7781895.
35. Tunggal JA, Helfrich I, Schmitz A, Schwarz H, Gunzel D, Fromm M, Kemler R, Krieg T, Niessen CM. E-cadherin is essential for in vivo epidermal barrier function by regulating tight junctions. EMBO J 2005, 24:1146-1156. 10.1038/sj.emboj.7600605, 556407, 15775979.
36. Knudsen KA, Sauer C, Johnson KR, Wheelock MJ. Effect of N-cadherin misexpression by the mammary epithelium in mice. J Cell Biochem 2005, 95:1093-1107. 10.1002/jcb.20469, 15838877.
37. Vleminckx K, Vakaet L, Mareel M, Fiers W, van Roy F. Genetic manipulation of E-cadherin expression by epithelial tumor cells reveals an invasion suppressor role. Cell 1991, 66:107-119. 10.1016/0092-8674(91)90143-M, 2070412.
38. Hart KC, Robertson SC, Kanemitsu MY, Meyer AN, Tynan JA, Donoghue DJ. Transformation and Stat activation by derivatives of FGFR1, FGFR3, and FGFR4. Oncogene 2000, 19:3309-3320. 10.1038/sj.onc.1203650, 10918587.
39. Sanchez-Heras E, Howell FV, Williams G, Doherty P. The fibroblast growth factor receptor acid box is essential for interactions with N-cadherin and all of the major isoforms of neural cell adhesion molecule. J Biol Chem 2006, 281:35208-35216. 10.1074/jbc.M608655200, 17005551.
40. Sutherland KD, Vaillant F, Alexander WS, Wintermantel TM, Forrest NC, Holroyd SL, McManus EJ, Schutz G, Watson CJ, Chodosh LA, Lindeman GJ, Visvader JE. c-myc as a mediator of accelerated apoptosis and involution in mammary glands lacking Socs3. EMBO J 2006, 25:5805-5815. 10.1038/sj.emboj.7601455, 1698901, 17139252.
41. Petersen H, Haldosen LA. EGF modulates expression of STAT5 in mammary epithelial cells. Exp Cell Res 1998, 243:347-358. 10.1006/excr.1998.4160, 9743594.
42. Gallego MI, Binart N, Robinson GW, Okagaki R, Coschigano KT, Perry J, Kopchick JJ, Oka T, Kelly PA, Hennighausen L. Prolactin, growth hormone, and epidermal growth factor activate Stat5 in different compartments of mammary tissue and exert different and overlapping developmental effects. Dev Biol 2001, 229:163-175. 10.1006/dbio.2000.9961, 11133161.
43. Vorherr H. Fibrocystic breast disease: pathophysiology, pathomorphology, clinical picture, and management. Am J Obstet Gynecol 1986, 154:161-179.
44. Santen RJ, Mansel R. Benign breast disorders. N Engl J Med 2005, 353:275-285. 10.1056/NEJMra035692, 16034013.
45. Logie JW. Mastopathia Cystica and Mammary Carcinoma. Cancer Res 1942, 2:394-397.
46. Berube J, Roussel L, Nattagh L, Rousseau S. Loss of cystic fibrosis transmembrane conductance regulator function enhances activation of p38 and ERK MAPKs, increasing interleukin-6 synthesis in airway epithelial cells exposed to Pseudomonas aeruginosa. J Biol Chem 2010, 285:22299-22307. 10.1074/jbc.M109.098566, 2903409, 20460375.
47. Worgall TS. Lipid metabolism in cystic fibrosis. Curr Opin Clin Nutr Metab Care 2009, 12:105-109. 10.1097/MCO.0b013e32832595b7, 19209467.
48. Nishimura R, Taira N, Sugata S, Takabatake D, Ohsumi S, Takashima S. Suspicious calcifications in benign breast lesions: a radio-pathologic correlation. Breast Cancer 2010, 18:33-6.
49. Provenzano PP, Inman DR, Eliceiri KW, Knittel JG, Yan L, Rueden CT, White JG, Keely PJ. Collagen density promotes mammary tumor initiation and progression. BMC Med 2008, 6:11. 10.1186/1741-7015-6-11, 2386807, 18442412.
50. Alexa O, Stolnicu S, Horvath E, Jung J. [The relationship between benign breast proliferation (fibrocystic mastopathy) and the appearance of breast carcinoma]. Rev Med Chir Soc Med Nat Iasi 2000, 104:101-109.
51. Fuster JJ, Sanz-Gonzalez SM, Moll UM, Andres V. Classic and novel roles of p53: prospects for anticancer therapy. Trends Mol Med 2007, 13:192-199. 10.1016/j.molmed.2007.03.002, 17383232.
52. Ullrich RL, Bowles ND, Satterfield LC, Davis CM. Strain-dependent susceptibility to radiation-induced mammary cancer is a result of differences in epithelial cell sensitivity to transformation. Radiat Res 1996, 146:353-355. 10.2307/3579468, 8752316.
53. Kuperwasser C, Hurlbut GD, Kittrell FS, Dickinson ES, Laucirica R, Medina D, Naber SP, Jerry DJ. Development of spontaneous mammary tumors in BALB/c p53 heterozygous mice. A model for Li-Fraumeni syndrome. Am J Pathol 2000, 157:2151-2159. 10.1016/S0002-9440(10)64853-5, 1885755, 11106587.
54. Radisky DC. Epithelial-mesenchymal transition. J Cell Sci 2005, 118:4325-4326. 10.1242/jcs.02552, 16179603.
55. Garber K. Epithelial-to-mesenchymal transition is important to metastasis, but questions remain. J Natl Cancer Inst 2008, 100:232-233. 239, 10.1093/jnci/djn032, 18270330.
56. Lee JM, Dedhar S, Kalluri R, Thompson EW. The epithelial-mesenchymal transition: new insights in signaling, development, and disease. J Cell Biol 2006, 172:973-981. 10.1083/jcb.200601018, 2063755, 16567498.
57. Hugo HJ, Kokkinos MI, Blick T, Ackland ML, Thompson EW, Newgreen DF. Defining the E-cadherin repressor interactome in epithelial-mesenchymal transition: the PMC42 model as a case study. Cells Tissues Organs 2011, 193:23-40. 10.1159/000320174, 21051859.